Parkinson’s disease may be biologically present long before it becomes clinically obvious, and a new study is drawing attention to a problem that could complicate diagnosis even after laboratory testing has identified the disease-associated protein. In a paper published in npj Parkinson’s Disease, C. Zuo, W. Li, W. Chen and colleagues examine what they describe as the “clinical masking effect” in patients who test positive for Parkinson’s disease through a seed amplification assay. Their work proposes that the same underlying pathological process can produce very different clinical pictures, creating a gap between molecular evidence and the symptoms physicians see in the examination room.

The study focuses on patients who are SAA-positive, meaning that their biological samples contain misfolded alpha-synuclein capable of triggering the aggregation of normally folded alpha-synuclein in a laboratory reaction. Alpha-synuclein is a neuronal protein involved in synaptic function, but in Parkinson’s disease it can adopt abnormal conformations and assemble into toxic structures. Seed amplification assays exploit this property: a minute quantity of disease-associated alpha-synuclein is placed in a reaction mixture, where it can act as a “seed” and accelerate the formation of detectable aggregates. The approach has become one of the most important molecular tools for identifying Parkinson’s pathology, particularly in research settings where conventional clinical criteria may be uncertain.

A positive molecular test, however, does not guarantee a textbook Parkinson’s presentation. Some individuals may show relatively mild motor impairment despite evidence of alpha-synuclein pathology, while others may develop rapidly progressive rigidity, gait dysfunction, cognitive symptoms or autonomic disturbances. This mismatch is central to the paper’s argument. The authors frame the clinical masking effect as a phenomenon in which compensatory neural systems, disease distribution, coexisting pathology or differences in vulnerability conceal the biological burden of disease. In practical terms, two people with comparable evidence of misfolded alpha-synuclein may not look alike when assessed using movement symptoms alone.

The concept challenges an assumption that has shaped Parkinson’s diagnosis for decades: that the severity and type of symptoms provide a reliable proxy for the underlying molecular process. Clinical scales remain essential, but they measure the consequences of disease rather than the disease mechanism itself. Motor signs emerge from the failure of interconnected neural circuits, especially those involving dopamine-producing neurons in the substantia nigra and their connections with the striatum. Yet the timing and extent of that failure can be altered by reserve capacity, medication exposure, network compensation and damage outside the classic motor pathway. As a result, symptom-based classification may compress biologically distinct patients into the same category or separate patients who share a common pathology.

The researchers describe this problem through a central mechanistic dichotomy. Although the paper’s title does not reduce the phenomenon to a single clinical division, the proposed framework emphasizes that Parkinson’s disease can be understood through more than one interacting axis: the presence of alpha-synuclein pathology and the way that pathology is distributed, expressed and modified across the nervous system. One axis concerns the central mechanism itself—where abnormal protein accumulates and which circuits are affected. The other concerns the visible phenotype, including motor, cognitive, sensory and autonomic manifestations. When these axes do not align, a patient can be molecularly positive but clinically atypical, or clinically suggestive but difficult to classify using conventional criteria.

That distinction is important because Parkinson’s disease is not a single, uniform disorder. Neuropathological studies have shown that alpha-synuclein can involve the brainstem, limbic regions, cortex and peripheral nervous system in different patterns. The biological consequences depend not only on whether aggregates are present, but also on their conformation, cellular location, propagation route and interaction with inflammation, mitochondrial dysfunction and impaired protein clearance. These processes may help explain why one patient first develops tremor, another experiences balance problems, and another presents with sleep disturbance, constipation, depression or loss of smell years before motor symptoms become prominent.

The study’s second major contribution is its emphasis on a peripheral diagnostic panel. Rather than relying on a single central nervous system signal or on clinical observation alone, the authors propose using accessible biological indicators to capture the disease from outside the brain. Peripheral diagnostics could include molecular evidence of alpha-synuclein, markers of neuronal injury, immune or inflammatory activity, autonomic dysfunction and related physiological changes. The value of such a panel would not necessarily be to replace the seed amplification assay, but to add context: a molecular result could be interpreted alongside signals that indicate disease burden, likely clinical expression or the involvement of particular biological pathways.

This approach reflects a broader shift in neurology toward multidimensional diagnosis. A useful panel must do more than distinguish patients with Parkinson’s disease from healthy controls. It should ideally identify people at an early stage, separate Parkinson’s disease from clinically similar disorders, predict the likely trajectory and monitor biological responses to treatment. Such goals are technically demanding. Biomarkers measured in blood, skin or other peripheral tissues may be present at very low concentrations, may vary with collection and storage conditions, and may be influenced by age, medication, kidney function, inflammation or unrelated neurological disease. A credible panel therefore requires analytical validation, standardized procedures and testing in diverse populations before it can be used routinely.

The implications extend beyond diagnosis. If clinical masking allows significant pathology to remain hidden, patients may enter clinical trials at different biological stages even when their symptom scores appear similar. That variation can make a potentially effective therapy seem weaker than it is, because the treatment is being tested in a mixed population with different mechanisms and rates of progression. A peripheral panel linked to a positive seed amplification assay could help researchers stratify participants, identify earlier disease and measure whether an experimental therapy is changing the underlying biology rather than merely improving symptoms. It could also support more precise counseling, although no biomarker should be interpreted as a perfect forecast for an individual patient.

The work arrives as Parkinson’s research moves from a largely symptom-defined field toward molecularly anchored medicine. Its central message is that a positive alpha-synuclein test is a major biological clue, but not the end of the diagnostic story. Understanding why pathology is clinically masked may require integrating protein misfolding, neural circuit vulnerability, peripheral involvement and the body’s compensatory responses. By connecting a central mechanistic model with a proposed peripheral diagnostic panel, Zuo, Li, Chen and their colleagues present a route toward detecting the disease as a biological process rather than waiting for its most recognizable symptoms to appear. The next challenge will be to determine how well this framework performs in independent cohorts and whether it can improve real-world diagnosis, prognosis and treatment selection.

Subject of Research: Clinical masking effects, alpha-synuclein seed amplification assay-positive Parkinson’s disease, central disease mechanisms and peripheral diagnostic biomarkers

Article Title: Decoding the clinical masking effect in SAA-positive Parkinson’s disease: from central mechanistic dichotomy to a peripheral diagnostic panel

Article References: Zuo, C., Li, W., Chen, W. et al. “Decoding the clinical masking effect in SAA-positive Parkinson’s disease: from central mechanistic dichotomy to a peripheral diagnostic panel.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01536-z

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01536-z

Keywords: Parkinson’s disease, alpha-synuclein, seed amplification assay, SAA-positive, clinical masking effect, peripheral biomarkers, diagnostic panel, neurodegeneration, precision medicine

Tags: alpha-synuclein misfolding detectionchallenges in Parkinson’s clinical diagnosisclinical masking in Parkinson’searly detection of Parkinson’s diseaselaboratory detection of alpha-synuclein aggregationmolecular biomarkers for Parkinson’sneurodegenerative disease diagnostic panelsParkinson’s disease diagnosisperipheral diagnostic testing in Parkinson’spreclinical Parkinson’s disease biomarkersseed amplification assay for Parkinson’ssymptomatic variability in Parkinson’s disease